Florian Lordick
弗洛里安·洛迪克
MD, PhD
Professor of Oncology; Director, University Cancer Center Leipzig肿瘤学教授；莱比锡大学癌症中心主任
👥Biography 个人简介
Prof. Florian Lordick is a premier European authority on gastric and esophageal cancers at the University of Leipzig. He has shaped European treatment guidelines, contributed to ramucirumab registration trials, and advanced perioperative chemotherapy and HER2-targeted approaches in gastric cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Ramucirumab in Gastric Cancer
Contributed to the RAINBOW trial establishing ramucirumab plus paclitaxel as second-line standard for advanced gastric cancer, the first anti-angiogenic approval in this disease.
European GI Oncology Guidelines
Led development of ESMO clinical practice guidelines for gastric and esophageal cancers, harmonizing evidence-based standards across European oncology centers.
Representative Works 代表性著作
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW)
The Lancet Oncology (2014)
Phase III trial demonstrating OS benefit with ramucirumab-paclitaxel second-line, leading to regulatory approval globally.
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology (2022)
Comprehensive guideline update integrating immunotherapy, HER2 targeting, and molecular subtyping into European gastric cancer management standards.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 弗洛里安·洛迪克 的研究动态
Follow Florian Lordick's research updates
留下邮箱，当我们发布与 Florian Lordick（University Cancer Center Leipzig (UCCL), University of Leipzig）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment